Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00307489|
Recruitment Status : Completed
First Posted : March 28, 2006
Results First Posted : July 7, 2009
Last Update Posted : November 1, 2011
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
This study explores the efficacy, safety and tolerability of tenofovir DF (TDF) 300 mg once daily monotherapy versus the combination of emtricitabine 200 mg plus tenofovir DF 300 mg (FTC/TDF) once daily in subjects currently being treated with adefovir dipivoxil (Hepsera) for chronic hepatitis B who have persistent viral replication (detectable hepatitis B virus deoxyribonucleic acid [HBV DNA]).
Subjects with confirmed (within 4 weeks) plasma HBV DNA ≥ 400 copies/mL during double blind treatment at Week 24 or any time thereafter have the option of receiving 12 weeks of open-label FTC/TDF which may be continued through the end of the 168-week treatment period if there is a virologic response (HBV DNA < 400 copies/mL). Alternatively, subjects with confirmed HBV DNA < 400 copies/mL at or any time after Week 24 of double-blind treatment may continue blinded therapy up to Week 168 at the discretion of the investigator. If, in the investigator's opinion, it is felt that continued blinded treatment beyond 24 weeks in subjects with confirmed HBV DNA ≥ 400 copies/mL is not beneficial, the subject may discontinue the study and begin commercially available HBV therapy rather than initiate open-label FTC/TDF.
|Condition or disease||Intervention/treatment||Phase|
|Chronic Hepatitis B||Drug: tenofovir DF Drug: emtricitabine /tenofovir DF||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||106 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine Plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects Currently Being Treated With Adefovir Dipivoxil for Chronic Hepatitis B and Having Persistent Viral Replication|
|Study Start Date :||March 2006|
|Actual Primary Completion Date :||January 2008|
|Actual Study Completion Date :||October 2010|
Drug: tenofovir DF
300 mg tablet, once daily (QD)
Drug: emtricitabine /tenofovir DF
emtricitabine 200 mg/tenofovir DF 300 mg once daily (combination tablet)
- Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 48 [ Time Frame: 48 weeks ]
- Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 48 [ Time Frame: 48 Weeks ]
- Change From Baseline in log10 Plasma HBV DNA Levels at Week 48 [ Time Frame: 48 Weeks ]
- Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 48 [ Time Frame: 48 Weeks ]
- Percentage of Participants With Normal ALT at Week 48 [ Time Frame: 48 Weeks ]ULN for males = 43 U/L; 34 U/L for females
- Percentage of Participants With Normalized ALT at Week 48 [ Time Frame: 48 Weeks ]Subjects with elevated ALT at baseline that return to normal by Week 48.
- Hepatitis B Early Antigen (HBeAg) Loss at Week 48 [ Time Frame: 48 Weeks ]Defined as having negative serum HBeAg for subjects with positive HBeAg at baseline.
- HBeAg Seroconversion at Week 48 [ Time Frame: 48 Weeks ]Defined as having negative serum HBeAg and positive serum antibody to HBeAg [anti-HBe] for subjects with positive serum HBeAg at baseline.
- HBsAg Loss at Week 48 [ Time Frame: 48 Weeks ]Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline.
- Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 48 [ Time Frame: 48 Weeks ]Defined as having negative serum HBsAg and positive serum antibody to HBsAg [anti-HBs] for subject with positive serum HBsAg at baseline.
- Change From Baseline in log10 Plasma HBV DNA Levels at Week 168 [ Time Frame: 168 weeks ]
- Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 168 [ Time Frame: 168 weeks ]
- Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 168 [ Time Frame: 168 weeks ]
- Percentage of Participants With Normal ALT at Week 168 [ Time Frame: 168 weeks ]ULN for males = 43 U/L; ULN for females = 34 U/L
- Percentage of Participants With Normalized ALT at Week 168 [ Time Frame: 168 weeks ]Subjects with elevated ALT at baseline that return to normal by Week 48.
- Hepatitis B Early Antigen (HBeAg) Loss at Week 168 [ Time Frame: 168 weeks ]Defined as having negative serum HBeAg for subjecst with positive HBeAg at baseline.
- Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 168 [ Time Frame: 168 weeks ]Defined as having negative serum BHsAg and positive serum antibody to HBsAg (anti-HBs) for subject with positive serum BHsAg at baseline.
- HBsAg Loss at Week 168 [ Time Frame: 168 weeks ]Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline.
- Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 168 [ Time Frame: 168 weeks ]P-values were from a Cochran-Mantel-Haenszel test, controlling for baseline HBeAg status and prior lamivudine use.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 69 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- 18 through 69 years of age, inclusive
- Chronic HBV infection, defined as positive serum HBsAg for at least 6 months
Active chronic HBV infection with all the following:
- Currently treated with adefovir dipivoxil 10 mg QD (for at least 24 weeks but not more than 96 weeks)
- HBeAg positive or negative at screening
- Plasma HBV DNA >/= 1000 copies/mL at screening (irrespective of HBeAg status)
- Serum ALT less than 10 times the upper limit of normal (ULN)
- Calculated creatinine clearance of at least 70 mL/min using the Cockcroft-Gault formula
- Hemoglobin at least 8 g/dL
- Neutrophils at least 1,000 /mm3
- Nucleoside naive except for lamivudine (>/= 12 weeks of therapy)
- Negative serum beta human chorionic gonadotropin
- Compliant with adefovir dipivoxil
- Willing and able to provide written informed consent
- Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study
- Male or females of reproductive potential who are unwilling to use an effective method of contraceptive while enrolled in the study. For males, condoms should be used and for females, a barrier contraception method should be used
- Decompensated liver disease defined as conjugated bilirubin greater than 1.5 times ULN, prothrombin time (PT) greater than 1.5 times ULN, platelets less than 75,000/mm3, serum albumin less than 3.0 g/dL, or prior history of clinical hepatic decompensation (eg, ascites, jaundice, encephalopathy, variceal hemorrhage)
- Prior use of tenofovir DF or entecavir
- Received treatment with interferon or pegylated interferon within 6 months of the screening visit
- Evidence of hepatocellular carcinoma (HCC); for example, alpha-fetoprotein greater than 50 ng/mL or by any other standard of care measure.
- Co-infection with HCV (based on serology), human immunodeficiency virus (HIV), or hepatitis delta virus (HDV)
- Significant renal, cardiovascular, pulmonary, or neurological disease.
- Received solid organ or bone marrow transplantation.
- Is currently receiving therapy with immunomodulators (eg, corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents capable of modifying renal excretion
- Has proximal tubulopathy
- Known hypersensitivity to the study drugs (tenofovir DF or emtricitabine/tenofovir DF), the metabolites (tenofovir or emtricitabine) or formulation excipients
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00307489
|United States, California|
|San Francisco, California, United States, 94115|
|San Jose, California, United States, 95128|
|United States, New York|
|Flushing, New York, United States, 11355|
|New York, New York, United States, 10013|
|New York, New York, United States, 10016|
|New York, New York, United States, 10021|
|United States, Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19107|
|United States, Virginia|
|Fairfax, Virginia, United States, 22031|
|Norfolk, Virginia, United States, 23502|
|Richmond, Virginia, United States, 23249|
|Angers, France, 49933|
|Clichy, France, 92110|
|Lille, France, 59037|
|Lyon, France, 69288|
|Marseille, France, 13285|
|Rouen, France, 76031|
|Strasbourg, France, 67091|
|Berlin, Germany, 10969|
|Berlin, Germany, 13353|
|Bonn, Germany, 53105|
|Erlangen, Germany, 91054|
|Essen, Germany, 45122|
|Frankfurt, Germany, 60590|
|Hamburg, Germany, 20999|
|Hannover, Germany, 30623|
|Herne, Germany, 44623|
|Munchen, Germany, 81377|
|Sevilla, Spain, 41014|
|Study Director:||Stephen J Rossi, PharmD||Gilead Sciences|
|Responsible Party:||Gilead Sciences|
|Other Study ID Numbers:||
|First Posted:||March 28, 2006 Key Record Dates|
|Results First Posted:||July 7, 2009|
|Last Update Posted:||November 1, 2011|
|Last Verified:||October 2011|
Hepatitis B, Chronic
Digestive System Diseases
Hepatitis, Viral, Human
RNA Virus Infections
DNA Virus Infections
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Molecular Mechanisms of Pharmacological Action